Anticancer potential of Salvia miltiorrhiza and its tanshinones: an efficacy perspective

References

• Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of Clinical Pharmacology. 2005;45(12):1345–1359.
   PubMed Web of Science ®Google Scholar
• Dong Y, Morris-Natschke SL, Lee KH. Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Natural Product Reports. 2011;28(3):529–542.
   PubMed Web of Science ®Google Scholar
• Wang X, Morris-Natschke SL, Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Medicinal Research Reviews. 2007;27(1):133–148.
   PubMed Web of Science ®Google Scholar
• Nakao M, Fukushima T. On the chemical composition of Salvia miltiorrhiza (Chinese drug Tan-shen). Yakugaku Zasshi. 1934;54:844–858.
   Google Scholar
• Bi HC, Zuo Z, Chen X, et al. Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases. Xenobiotica. 2008;38(2):185–222.
   PubMed Web of Science ®Google Scholar
• Don MJ, Shen CC, Syu WJ, Ding YH, Sun CM. Cytotoxic and aromatic constituents from Salvia miltiorrhiza. Phytochemistry. 2006;67(5):497–503.
   PubMed Web of Science ®Google Scholar
• Gu M, Zhang G, Su Z, Ouyang F. Identification of major active constituents in the fingerprint of Salvia miltiorrhiza Bunge developed by high-speed counter-current chromatography. Journal of Chromatography A. 2004;1041(1–2):239–243.
   Web of Science ®Google Scholar
• Wei YJ, Li SL, Li P. Simultaneous determination of seven active components of Fufang Danshen tablet by high performance liquid chromatography. Biomedical Chromatography. 2007;21(1):1–9.
   Web of Science ®Google Scholar
• Yang M, Liu A, Guan S, Sun J, Xu M, Guo D. Characterization of tanshinones in the roots of Salvia miltiorrhiza (Dan-shen) by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 2006;20(8):1266–1280.
   Web of Science ®Google Scholar
• Liu AH, Li L, Xu M, Lin YH, Guo HZ, Guo DA. Simultaneous quantification of six major phenolic acids in the roots of Salvia miltiorrhiza and four related traditional Chinese medicinal preparations by HPLC–DAD method. Journal of Pharmaceutical and Biomedical Analysis. 2006;41(1):48–56.
   PubMed Web of Science ®Google Scholar
• Ma L, Zhang X, Guo H, Gan Y. Determination of four water-soluble compounds in Salvia miltiorrhiza Bunge by high-performance liquid chromatography with a coulometric electrode array system. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2006;833(2):260–263.
   PubMed Web of Science ®Google Scholar
• Kong DY. Chemical constituents of Salvia miltiorrhiza (Danshen). Zhongguo Yiyao Gongye Zazhi. 1989;20:279–285.
   Google Scholar
• Zeng Y, Song JX, Shen XC. Herbal remedies supply a novel prospect for the treatment of atherosclerosis: a review of current mechanism studies. Phytotherapy Research: PTR. 2012;26(2):159–167.
   Web of Science ®Google Scholar
• Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 2012;220(1):3–10.
   PubMed Web of Science ®Google Scholar
• Ho JH, Hong CY. Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection. Journal of Biomedical Science. 2011;18:30.
   PubMed Web of Science ®Google Scholar
• Jia Y, Huang F, Zhang S, Leung SW. Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? A systematic review of randomized controlled trials. International Journal of Cardiology. 2012;157(3):330–340.
   Web of Science ®Google Scholar
• Zhang Y, Jiang P, Ye M, Kim SH, Jiang C, Lu J. Tanshinones: sources, pharmacokinetics and anti-cancer activities. International Journal of Molecular Sciences. 2012;13(10):13621–13666.
   PubMed Web of Science ®Google Scholar
• Wang X, Nakagawa-Goto K, Bastow KF, et al. Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents. Journal of Medicinal Chemistry. 2006;49(18):5631–5634.
   Web of Science ®Google Scholar
• Sashidhara KV, Rosaiah JN, Kumar M, et al. Neo-tanshinlactone inspired synthesis, in vitro evaluation of novel substituted benzocoumarin derivatives as potent anti-breast cancer agents. Bioorganic and Medicinal Chemistry Letters. 2010;20(23):7127–7131.
   Web of Science ®Google Scholar
• Dong Y, Shi Q, Pai HC, et al. Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. Journal of Medicinal Chemistry. 2010;53(5):2299–2308.
   PubMed Web of Science ®Google Scholar
• Dong Y, Nakagawa-Goto K, Lai CY, Morris-Natschke SL, Bastow KF, Lee KH. Antitumor agents 287. Substituted 4-amino-2H-pyran-2-one (APO) analogs reveal a new scaffold from neo-tanshinlactone with in vitro anticancer activity. Bioorganic and Medicinal Chemistry Letters. 2011;21(8):2341–2344.
   Web of Science ®Google Scholar
• Wang X, Bastow KF, Sun C-M, et al. Antitumor agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. Journal of Medicinal Chemistry. 2004;47(23):5816–5819.
   PubMed Web of Science ®Google Scholar
• Tian XH, Wu JH. Tanshinone derivatives: a patent review (January 2006 – September 2012). Expert Opinion on Therapeutic Patents. 2013;23(1):19–29.
   Google Scholar
• Zhang J, Huang M, Guan S, et al. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. Journal of Pharmacology and Experimental Therapeutics. 2006;317(3):1285–1294.
   Web of Science ®Google Scholar
• Guo ZJ, Zhang Y, Tang X, Li H, Sun QS. Pharmacokinetic interaction between tanshinones and polyphenolic extracts of Salvia miltiorrhiza Bunge after intravenous administration in rats. Biological and Pharmaceutical Bulletin. 2008;31(8):1469–1474.
   Web of Science ®Google Scholar
• Yang S, Zhang K, Lin X, et al. Pharmacokinetic comparisons of single herb extract of Fufang Danshen preparation with different combinations of its constituent herbs in rats. Journal of Pharmaceutical and Biomedical Analysis. 2012;67–68:77–85.
   Web of Science ®Google Scholar
• Xue M, Cui Y, Wang H, Luo Y, Zhang B, Zhou Z. Pharmacokinetics of cryptotanshinone and its metabolite in pigs. Acta Pharmaceutica Sinica. 1999;34(2):81–84.
   Google Scholar
• Hao H, Wang G, Li P, Li J, Ding Z. Simultaneous quantification of cryptotanshinone and its active metabolite tanshinone IIA in plasma by liquid chromatography/tandem mass spectrometry (LC–MS/MS). Journal of Pharmaceutical and Biomedical Analysis. 2006;40(2):382–388.
   Web of Science ®Google Scholar
• Song M, Hang TJ, Zhang ZX, Du R, Chen J. Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2005; 827(2):205–209.
   Web of Science ®Google Scholar
• Liu M, Wang Q, Liu F, et al. UDP-glucuronosyltransferase 1A compromises intracellular accumulation and anti-cancer effect of tanshinone IIA in human colon cancer cells. PLoS One. 2013;8(11):e79172.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhu J, Du Z, Qin B. Preparation and pharmacokinetic evaluation of tanshinone IIA solid lipid nanoparticles. Drug Development and Industrial Pharmacy. 2005;31(6):551–556.
   PubMed Web of Science ®Google Scholar
• Zhang WL, Liu JP, Liu XX, Chen ZQ. Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats. Yao xue xue bao = Acta Pharmaceutica Sinica. 2009;44(12):1421–1428.
   Google Scholar
• Li Q, Wang Y, Feng N, Fan Z, Sun J, Nan Y. Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma. Journal of Drug Targeting. 2008;16(10):725–732.
   PubMed Web of Science ®Google Scholar
• Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2010;11(2):582–587.
   PubMed Web of Science ®Google Scholar
• Wang Y, Song D, Costanza F, et al. Targeted delivery of tanshinone IIA-conjugated mPEG-PLGA-PLL-cRGD nanoparticles to hepatocellular carcinoma. Journal of Biomedical Nanotechnology. 2014;10(11):3244–3252.
   PubMed Web of Science ®Google Scholar
• Fan Z, Li J, Dong C. Preparation and study on the inclusion complexes of two tanshinone compounds with β-cyclodextrin. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2005;61(1–2):135–140.
   Web of Science ®Google Scholar
• Ma H, Fan Q, Yu J, Xin J, Zhang C. Anticancer activities of tanshinone microemulsion against hepatocellular carcinoma in vitro and in vivo. Molecular Medicine Reports. 2013;7(1):59–64.
   PubMed Web of Science ®Google Scholar
• Ma H, Fan Q, Yu J, Xin J, Zhang C. Novel microemulsion of tanshinone IIA, isolated from Salvia miltiorrhiza Bunge, exerts anticancer activity through inducing apoptosis in hepatoma cells. Am J Chin Med. 2013;41(1):197–210.
   Web of Science ®Google Scholar
• Zhang J, Li Y, Fang X, Zhou D, Wang Y, Chen M. TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy. International Journal of Pharmaceutics. 2014;476(1–2):185–198.
   PubMed Web of Science ®Google Scholar
• Liang WF, Li ZW, Ji Set al. Microbial glycosylation of tanshinone IIA by Cunninghamella elegans AS 3.2028. Royal Society of Chemistry Advances. 2015;5:63753–63756.
   Web of Science ®Google Scholar
• Li G, Shan C, Liu L, et al. Tanshinone IIA inhibits HIF-1alpha and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway. PLoS One. 2015;10(2):e0117440.
   Web of Science ®Google Scholar
• Lin C, Wang L, Wang H, Yang L, Guo H, Wang X. Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways. Journal of Cellular Biochemistry. 2013;114(9):2061–2070.
   Web of Science ®Google Scholar
• Chiu SC, Huang SY, Chen SP, Su CC, Chiu TL, Pang CY. Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo. Prostate Cancer and Prostatic Diseases. 2013;16(4):315–322.
   PubMed Web of Science ®Google Scholar
• Munagala R, Aqil F, Jeyabalan J, Gupta RC. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer. Cancer Letters. 2015;356(2 Pt B):536–546.
   Web of Science ®Google Scholar
• Chen L, Wang HJ, Xie W, Yao Y, Zhang YS, Wang H. Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo. Molecular Medicine Reports. 2014;9(6):2447–2452.
   Web of Science ®Google Scholar
• Su CC, Lin YH. Tanshinone IIA down-regulates the protein expression of ErbB-2 and up-regulates TNF-alpha in colon cancer cells in vitro and in vivo. International Journal of Molecular Medicine. 2008;22(6):847–851.
   Web of Science ®Google Scholar
• Su CC. Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II. Experimental and Therapeutic Medicine. 2012;3(3):555–559.
   Web of Science ®Google Scholar
• Zhang Y, Won SH, Jiang C, et al. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling. Pharmaceutical Research. 2012;29(6):1595–1608.
   Web of Science ®Google Scholar
• Su CC, Chien SY, Kuo SJ, Chen YL, Cheng CY, Chen DR. Tanshinone IIA inhibits human breast cancer MDA-MB-231 cells by decreasing LC3-II, Erb-B2 and NF-kappaBp65. Molecular Medicine Reports. 2012;5(4):1019–1022.
   Web of Science ®Google Scholar
• Shan YF, Shen X, Xie YK, et al. Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacologica Sinica. 2009;30(11):1537–1542.
   Web of Science ®Google Scholar
• Yuxian X, Feng T, Ren L, Zhengcai L. Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo. Tumori. 2009;95(6):789–795.
   Web of Science ®Google Scholar
• Xiao J, Zhang G, Qiu P, et al. Tanshinone IIA increases the bystander effect of herpes simplex virus thymidine kinase/ganciclovir gene therapy via enhanced gap junctional intercellular communication. PLoS One. 2013;8(7):e67662.
   Web of Science ®Google Scholar
• Lu Q, Zhang P, Zhang X, Chen J. Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer. International Journal of Molecular Medicine. 2009;24(6):773–780.
   Web of Science ®Google Scholar
• Zhang X, Zhang P, Chen J, Lu Q. A study on the effect of tanshinone IIA against human breast cancer in vivo. Journal of Sichuan University. Medical Science Edition. 2010;41(1):67–72.
   Google Scholar
• Yang L, Guo H, Dong L, Wang L, Liu C, Wang X. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells. Oncology Reports. 2014;32(3):1303–1311.
   Web of Science ®Google Scholar
• Chien SY, Kuo SJ, Chen YL, Chen DR, Cheng CY, Su CC. Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. Molecular Medicine Reports. 2012;5(1):282–286.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao J, Wang Y, et al. Tanshinone IIA triggers p53 responses and apoptosis by RNA polymerase II upon DNA minor groove binding. Biochemical Pharmacology. 2009;78(10):1316–1322.
   Web of Science ®Google Scholar
• Liu F, Yu G, Wang G, et al. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer. PLoS One. 2012;7(7):e42138.
   Web of Science ®Google Scholar
• Lee CY, Sher HF, Chen HW, et al. Anticancer effects of tanshinone I in human non-small cell lung cancer. Molecular Cancer Therapeutics. 2008;7(11):3527–3538.
   Web of Science ®Google Scholar
• He X, Zeng B, Liu H. Effect of tanshinone II A on acquired multi-drug resistance of S180’S tumor and expression of P-gp, LRP and TOPO II in mice. Journal of Traditional Chinese Medicine University of Hunan. 2010;30(7):16–18.
   Google Scholar
• Liu MZ, Huang YS, Xiao WQ. [No promoting effects of sodium tanshinone II-A sulfonate on growth and metastasis of Lewis carcinoma]. Zhongguo yao li xue bao = Acta Pharmacologica Sinica. 1991;12(6):534–537. Chinese.
   PubMed Web of Science ®Google Scholar
• Wang WQ, Liu L, Sun HC, et al. Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. Journal of Hematology and Oncology. 2012;5:69.
   PubMed Web of Science ®Google Scholar
• Tian HL, Yu T, Xu NN, et al. A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway. Cancer Letters. 2010;297(1):18–30.
   Web of Science ®Google Scholar
• Guerram M, Jiang ZZ, Yousef BA, et al. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: induction of cancer cell death by targeting apoptotic and metabolic signaling pathways. Oncotarget. 2015;6(26):21865–21877.
   PubMedGoogle Scholar
• Zhou LH, Hu Q, Sui H, et al. Tanshinone II–a inhibits angiogenesis through down regulation of COX-2 in human colorectal cancer. Asian Pacific Journal of Cancer Prevention: APJCP. 2012;13(9):4453–4458.
   Google Scholar
• Wang X, Wei Y, Yuan S, et al. Potential anticancer activity of tanshinone IIA against human breast cancer. International Journal of Cancer. Journal International du Cancer. 2005;116(5):799–807.
   Web of Science ®Google Scholar
• Chen J, Shi DY, Liu SL, Zhong L. Tanshinone IIA induces growth inhibition and apoptosis in gastric cancer in vitro and in vivo. Oncology Reports. 2012;27(2):523–528.
   PubMed Web of Science ®Google Scholar
• Zhou J, Xu XZ, Hu YR, Hu AR, Zhu CL, Gao GS. Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4+ T cells through the JAK2/STAT4/ perforin pathway. Asian Pacific Journal of Cancer Prevention: APJCP. 2014;15(6):2439–2445.
   Google Scholar
• Park IJ, Yang WK, Nam SH, et al. Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. Apoptosis: An International Journal on Programmed Cell Death. 2014;19(4):615–628.
   PubMed Web of Science ®Google Scholar
• Xu D, Lin TH, Li S, et al. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Letters. 2012;316(1):11–22.
   PubMed Web of Science ®Google Scholar
• Lin TH, Lee SO, Niu Y, et al. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) lead to promotion versus suppression of prostate cancer metastasis. The Journal of Biological Chemistry. 2013;288(27):19359–19369.
   Web of Science ®Google Scholar
• Lee HJ, Jung DB, Sohn EJ, et al. Inhibition of hypoxia inducible factor alpha and astrocyte-elevated gene-1 mediates cryptotanshinone exerted antitumor activity in hypoxic PC-3 cells. Evidence-Based Complementary and Alternative Medicine: eCAM. 2012;2012:390957.
   Web of Science ®Google Scholar
• Gong Y, Li Y, Lu Y, et al. Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. International Journal of Cancer. 2011;129(5):1042–1052.
   Web of Science ®Google Scholar
• Li Y, Gong Y, Li L, Abdolmaleky HM, Zhou JR. Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function. Molecular Carcinogenesis. 2013;52(7):535–543.
   PubMed Web of Science ®Google Scholar
• Nizamutdinova IT, Lee GW, Lee JS, et al. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis. 2008;29(10):1885–1892.
   PubMed Web of Science ®Google Scholar
• Tung YT, Chen HL, Lee CY, et al. Active component of Danshen (Salvia miltiorrhiza Bunge), tanshinone I, attenuates lung tumorigenesis via inhibitions of VEGF, cyclin A, and cyclin B expressions. Evidence-Based Complementary and Alternative Medicine: eCAM. 2013;2013:319247.
   Web of Science ®Google Scholar
• Tsai SL, Suk FM, Wang CI, et al. Anti-tumor potential of 15, 16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis. Biochemical Pharmacology. 2007;74(11):1575–1586.
   Web of Science ®Google Scholar
• Ye Y, Xu W, Zhong W, Li Y, Wang C. Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation. Molecular and Cellular Biochemistry. 2012;363(1–2):191–202.
   Web of Science ®Google Scholar
• Chen CH, Liu DZ, Fang HW, Liang HJ, Yang TS, Lin SY. Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer. Bioscience, Biotechnology, and Biochemistry. 2008;72(6):1586–1594.
   PubMed Web of Science ®Google Scholar
• Wang C, Du X, Yang R, et al. The prevention and treatment effects of tanshinone IIA on oestrogen/androgen-induced benign prostatic hyperplasia in rats. The Journal of Steroid Biochemistry and Molecular Biology. 2015;145:28–37.
   Web of Science ®Google Scholar
• Niu XH, Hua HY, Guo WJ, et al. [Clinical efficiency of tanshinone II A-sulfonate in treatment of liver fibrosis of advanced schistosomiasis]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2013;25(2):137–140. Chinese.
   Google Scholar
• Wang J, Lu W, Wang W, et al. Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients. Journal of Thoracic Disease. 2013;5(2):169–172.
   Web of Science ®Google Scholar
• Therapeutic effect of sodium tanshinone IIA sulfonate in patients with coronary heart disease. A double blind study. Shanghai Cooperative Group for the Study of Tanshinone IIA. Journal of Traditional Chinese Medicine. 1984;4(1):20–24. Chinese.
   Google Scholar
• Yang L, Zou XJ, Gao X, et al. Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Experimental and Molecular Medicine. 2009;41(7):508–516.
   PubMed Web of Science ®Google Scholar
• Tan X, Yang Y, Cheng J, Li P, Inoue I, Zeng X. Unique action of sodium tanshinone II-A sulfonate (DS-201) on the Ca2+ dependent BKCa activation in mouse cerebral arterial smooth muscle cells. European Journal of Pharmacology. 2011;656(1–3):27–32.
   PubMed Web of Science ®Google Scholar
• Chan SE, Lai HW, Su CC, et al. Effect of supplementation of tanshinone IIA and sodium tanshinone IIA sulfonate on the anticancer effect of epirubicin: an in vitro study. Evidence-Based Complementary and Alternative Medicine: eCAM. 2011;2011:841564.
   PubMed Web of Science ®Google Scholar
• Xu D, Lin TH, Zhang C, et al. The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells. The Prostate. 2012;72(7):803–816.
   Web of Science ®Google Scholar
• Xu Z, Wu L, Sun Y, et al. Tanshinone IIA pretreatment protects free flaps against hypoxic injury by upregulating stem cell-related biomarkers in epithelial skin cells. BMC Complementary and Alternative Medicine. 2014;14:331.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhang Z, Wu L, et al. Tanshinone IIA pretreatment renders free flaps against hypoxic injury through activating Wnt signaling and upregulating stem cell-related biomarkers. International Journal of Molecular Sciences. 2014;15(10):18117–18130.
   PubMed Web of Science ®Google Scholar
• Yang YM, Liu T. Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A. Journal of Sichuan University. Medical Science Edition. 2006;37(6):965–967. Chinese.
   Google Scholar
• Yang L, Gong YP, Yang YM, Luo S. A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintenance therapy of all-trans retinoic acid and arsenic trioxide. Journal of Sichuan University. Medical Science Edition. 2010;41(6):1065–1067. Chinese.
   Google Scholar
• Chen XL, Q. [Clinical observation on composite salviae dropping pill combined with FAM regimen in the treatment of gastric carcinoma]. Chinese Journal of Integrated Traditional and Western Medicine on Digestion. 2004;12:3. Chinese.
   Google Scholar
• Chen X, Liang Q, Li X, Zhang Y, Li J, Liang Z. [Effect of composite salviae dropping pill combined with chemotherapy in patients with colorectal carcinoma]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine. 2005;11:3. Chinese.
   Google Scholar
• Liang Q, Chen X, Li X, et al. [Evaluate the effect of composite salviae dropping pill combined with PPF regimen chemotherapy in patients with advanced esophageal carcinoma]. The Practical Journal of Cancer. 2005;20:3. Chinese.
   Google Scholar
• Chen X, Liang Q, Li X, et al. Effect of composite salviae dropping pill combined with chemotherapy in 41 cases with pancreatic carcinoma. Journal of Oncology. 2005;13(1):49–51. Chinese.
   Google Scholar
• Liang Q, Chen X, Li X, et al. [Evaluate the clinical effect of composite salviae dropping pill combined with chemotherapy in patients with hepatocellular carcinoma]. Chinese Archives of Traditional Chinese Medicine. 2006;24:3. Chinese.
   Google Scholar
• Liang Q, Zhang Y, Xie J, Li S, Luo H, Li X. [Clinical study on efficacy of compound Danshen droplet pill with chemotherapy in treating advanced non-small cell lung cancer]. Shanghai Journal of Chinese Medicine. 2007;41:3. Chinese.
   Google Scholar
• Ji B, Wang S, Jing B. Study of composite salviae miltiorrhizae injection on acute leukemia. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2004;13(22):2958–2959. Chinese.
   Google Scholar
• Jiang D, Li Q, Ding H, Huang J, Wang X, Shi L. Clinical research on prevention of recurrence by trans-umbilical-portal vein perfusion of Fufang Danshen in patients with hepatocellular carcinoma. The Practical Journal of Cancer. 2007;22(4):39–41. Chinese.
   Google Scholar
• Li Y, Zhu J, Li Y, Wang Y, Zhang W. The efficiencies of hepatic artery infusion with the liquid compound of Radix Salvia Miltiorrhizae and segmental hepatic artery chemoembolization in HCC. Chinese Imaging Journal of Integrated Traditional and Western Medicine. 2006;4(5):352–355. Chinese.
   Google Scholar
• Liu AH, Lin YH, Yang M, Sun JH, Guo H, Guo DA. High-performance liquid chromatographic determination of tanshinones in the roots of Salvia miltiorrhiza and related traditional Chinese medicinal preparations. Journal of Pharmacy and Pharmaceutical Sciences: A Publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2006;9(1):1–9.
   Google Scholar